



EV524615550US

Express Mail Label Number

June 23, 2005

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 1.00 2 3 JUN 2005

IN RE PCT NATIONAL STAGE APPLICATION OF ALTMANN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/14741

FILED: 22 DECEMBER 2003

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2-AMINO-PHENYL

METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID

HORMONE

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/14741, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Susan Hess

Attorney for Applicants

Reg. No. 37,350

Novartis

Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 778-7859

Date: June 23, 2005

FORM PTO-1449 (REV. 7-85)

(Use several sheets if necessary)

MENT OF COMMERCE PATENT D TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

Not Yet Assigned APPLICANT ALTMANN ET AL. **FILING DATE**

Group

JC20 Rec'd PCT/PTO 2 3 JUN 2005

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,387,223	6/7/83	Yamamoto Michihiro et al.			
	АВ	3,812,257	5/21/74	Inaha et al.			
	AC	5,773,663	6/30/98	Rehnig et al.			
	AD	5,856,503	1/5/99	Maerki et al.			
_	AE	3,925,548	12/9/75	Pfeffingen			
	AF	6,211,244	4/3/01	Delmar et al.			
	AG						-
	АН	ALL REFERENCES	CONSIDE	RED EXCEPT WHERE LINE	D THRO	UGH. /T.N./	
	Al					**	
	AJ				-	,	
	AK					_	·
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
 AM	CH 612 186	7/13/79	Swiss				
AN	GB 1 353 789	5/22/74	Great Britain				
AO	WO 02/24683	3/28/02	WIPO				
 AP	WO 02/102782	12/27/02	WIPO			\Box	
AQ	ALL REFERENCI	ES CONSIL	DERED EXCEPT WHERE LIF	VED I HI	ROUGH. /I		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/T.N./	AR	Russell et al., "Synthesis and Renal Vasodilator Activity of Substituted '4-aklyl(aryl)-2-oxoquinazolin-1-y1!alkanoic Acids", European Journal of Medicinal Chemistry, Vol. 27, No. 3, pp. 277-284, (1992)-				
/T.N./	AS	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002935850 & Miyagishi et al, "General Pharmaceutical Studies on Ciproquazone (SL-573) and its Metabolites" OYL YAKURI, vol. 18, No. 1, pp. 9-22 (1979)				
/T.N./	АТ	Masai, et al, "Carbon-13 Nuclea	r Magnetic Resonance Studies of Anti-Inflammatory 2(1H)- narmaceutical Bulletin, Vol. 25, No. 11, pp. 3018-3022, (1977)			
EXAMIN	ER	/Tamthom Truong/	DATE CONSIDERED 06/10/2008			

*EXAMINER:

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

FORM PTO-1449
(REV. 7-85)
U.S. DE MENT OF COMMERCE PATENTS, J.D. TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

PALSTARA APPLICATION NO. Not Yet Assigned APPLICANT ALTMANN ET AL. FILING DATE

Group

(Use several sheets if necessary)

JC20 Rec'd PCT/PTO 2 3 JUN 2005

EXAMINER INITIAL	ОТН	ER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
	DA	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280289 retrieved from STN accession no. 503745 rn: 37554-38-4 & Mardente et al, "GLC-ECD Determination of 1-(2-Hydroxyethyl)-3-Hydroxy-7-Chloro-1,3-Dihydro-5-(0-Fluorophenyl)-2H-1,4-Benzodoazepin-2-one (SAS 643) in Plasma and Urine and Identification of its main Biotransformation Produscts" Therapeutic Drug Monitoring, Vol. 3, No. 4, pp. 351-356 (1981)
	DB	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280290 retrieved from STN accession no. 1142 database accession no. 1994:244939 rn: 154374-68-2P; 154374-67-1 & M. I. Jaeda at al, "Synthesis of Some Novel 2(1H)-Quinazolinones and 2-Thioxoanalogs from Newly Synthesized 1-acyl-3-alkoxyphenylureas and Tioureas", Journal of Chemical Technology and Biotechnology, Vol. 58, No. 4, pp. 391-394, (1993)
	DC	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280291 retrieved from STN accession no. 1277 database accession no. 1981:461773 rn 78350-38-6 & JP 55 143959 (Shionogi and Co.) 1980
	DD	Database Crossfire Beilstein 'Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, XP002280292 Database Accession no. 6810088 & Berger et al., ACTA Crystallogr. Sect. C: Cryst. Struct. Commun, Vol. 50, pp. 773-775, (1994)
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	
EXAMINER	₹	DATE CONSIDERED